Travere Therapeutics

Travere Therapeutics, Inc. is a biopharmaceutical company dedicated to the development and commercialization of therapies for rare diseases, particularly those affecting the kidney, liver, and metabolic systems. The company's marketed products include Chenodal, used for treating radiolucent gallbladder stones; Cholbam, targeting bile acid synthesis disorders; and Thiola, which is prescribed for cystinuria. In addition to its existing products, Travere is advancing its pipeline candidate, Sparsentan, which is currently in Phase III clinical trials for the treatment of focal segmental glomerulosclerosis and immunoglobulin A nephropathy, both of which are serious kidney conditions. The company collaborates with various organizations, including the National Institutes of Health, to explore potential treatments for NGLY1 deficiency and Alagille syndrome. Founded in 2011 and headquartered in San Diego, California, Travere Therapeutics aims to deliver life-changing therapies to individuals suffering from rare diseases.